The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
Open accessAbstract
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R‐CHOP remains the mainstay of therapy and can achieve long‐term disease control in nearly 90% of patients presenting with limited‐stage and in up to 60% of those presenting with advanced stages. Advances on the understanding of the genetic landscape and molecular features of DLBCL have identified high‐risk subsets with poor outcomes to chemo‐immunotherapy that are actively being studied in clinical trials. Novel therapies could potentially improve outcomes for patients with high‐risk disease. Studies evaluating risk‐adapted therapy based on classification by cell of origin (COO) and molecular features are ongoing. Developments in the fields of immunotherapy, mostly with adoptive T‐cell therapy, have significantly improved the outcomes of patients with relapsed refractory disease. In this review, we will summarize the recent data and discuss ongoing efforts to improve DLBCL treatment in the frontline and relapsed refractory settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 1×
“The approval of liso-cel was based on the phase 1 TRANSCEND NHL 001 trial in which liso-cel induced an ORR of 73% and a CR in 53% of patients with heavily pretreated large B-cell lymphoma.(67) At a median followup of 12 months, the median DOR had not yet been reached.”
MethodChimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M., Grogan, T. M., LeBlanc, M., Carlin, S., Chase, E., & Fisher, R. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390104 · Cited by 1,004
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
Younes, A., Sehn, L. H., Johnson, P., Zinzani, P. L., Hong, X., Zhu, J., Patti, C., Belada, D., Samoilova, O., Suh, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02403 · Cited by 608
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J. S., Siebert, R., Kuruvilla, J., Klasa, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212191 · Cited by 587
Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2493 · Cited by 581
Cunningham, D., Hawkes, E. A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J. A., McMillan, A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60313-x · Cited by 561
Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., Nagy, Z., Obr, A., Gaidano, G., André, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30225-4 · Cited by 533
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5246 · Cited by 497
Roschewski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E. S., Staudt, L. M., Lai, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70106-3 · Cited by 463
Pasquini, M. C., Hu, Z.-H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M. A., Phillips, C. L., Keating, A., Frigault, M. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003092 · Cited by 450
Bartlett, N. L., Wilson, W. H., Jung, S.-H., Hsi, E. D., Maurer, M. J., Pederson, L. D., Polley, M.-Y. C., Pitcher, B. N., Cheson, B. D., Kahl, B. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01994 · Cited by 434
Ennishi, D., Jiang, A., Boyle, M., Collinge, B., Grande, B. M., Ben-Neriah, S., Rushton, C., Tang, J., Thomas, N., Slack, G. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01583 · Cited by 414
Maurer, M. J., Ghesquières, H., Jais, J.-P., Witzig, T. E., Haioun, C., Thompson, C. A., Delarue, R., Micallef, I. N., Peyrade, F., Macon, W. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5866 · Cited by 411
Vercellino, L., Di Blasi, R., Kanoun, S., Tessoulin, B., Rossi, C., D'Aveni-Piney, M., Obéric, L., Bodet-Milin, C., Bories, P., Olivier, P., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003001 · Cited by 410
Scott, D. W., Mottok, A., Ennishi, D., Wright, G. W., Farinha, P., Ben-Neriah, S., Kridel, R., Barry, G. S., Hother, C., Abrisqueta, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2383 · Cited by 405
Ansell, S. M., Minnema, M. C., Johnson, P., Timmerman, J. M., Armand, P., Shipp, M. A., Rodig, S. J., Ligon, A. H., Roemer, M. G. M., Reddy, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00766 · Cited by 353
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., Casasnovas, O., Hamad, N., Zijlstra, J. M., Bakhshi, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30120-4 · Cited by 339
Gutiérrez, G., Cardesa‐Salzmann, T. M., Climent, F., González-Barca, E. M., Mercadal, S., Mate, J. L., Sancho, J., Arenillas, L., Serrano, S., Escoda, L., et al. (2011) · Blood · doi:10.1182/blood-2010-12-322362 · Cited by 334
Van Den Neste, E., Schmitz, N., Mounier, N., Gill, D., Linch, D., Trneny, M., Milpied, N., Radford, J., Ketterer, N., Shpilberg, O., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.213 · Cited by 306
Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., et al. (2015) · Blood · doi:10.1182/blood-2014-09-598763 · Cited by 300
Persky, D. O., Unger, J. M., Spier, C. M., Stea, B., LeBlanc, M., McCarty, M. J., Rimsza, L. M., Fisher, R. I., & Miller, T. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6929 · Cited by 294
Gisselbrecht, C., Schmitz, N., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Milpied, N. J., Radford, J., Ketterer, N., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9416 · Cited by 284
Thieblemont, C., Briere, J., Mounier, N., Voelker, H.-U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4423 · Cited by 275
Dührsen, U., Müller, S., Hertenstein, B., Thomssen, H., Kotzerke, J., Mesters, R., Berdel, W. E., Franzius, C., Kroschinsky, F., Weckesser, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8093 · Cited by 249
Dunleavy, K., Fanale, M. A., Abramson, J. S., Noy, A., Caimi, P. F., Pittaluga, S., Parekh, S., Lacasce, A., Hayslip, J. W., Jagadeesh, D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30177-7 · Cited by 230
CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0297 · Cited by 228
Garfall, A. L., Dancy, E. K., Cohen, A. D., Hwang, W.-T., Fraietta, J. A., Davis, M. M., Levine, B. L., Siegel, D. L., Stadtmauer, E. A., Vogl, D. T., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000600 · Cited by 226
Mamot, C., Klingbiel, D., Hitz, F., Renner, C., Pabst, T., Driessen, C., Mey, U., Pless, M., Bargetzi, M., Krasniqi, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9846 · Cited by 186
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Vercellino, L., Cottereau, A.-S., Casasnovas, O., Tilly, H., Feugier, P., Chartier, L., Fruchart, C., Roulin, L., Oberic, L., Pica, G. M., et al. (2020) · Blood · doi:10.1182/blood.2019003526 · Cited by 186
Schuster, S. J., Bartlett, N. L., Assouline, S., Yoon, S.-S., Bosch, F., Sehn, L. H., Cheah, C. Y., Shadman, M., Gregory, G. P., Ku, M., et al. (2019) · Blood · doi:10.1182/blood-2019-123742 · Cited by 182
Hamadani, M., Radford, J., Carlo-Stella, C., Caimi, P. F., Reid, E., O’Connor, O. A., Feingold, J. M., Ardeshna, K. M., Townsend, W., Solh, M., et al. (2021) · Blood · doi:10.1182/blood.2020007512 · Cited by 178
Morschhauser, F., Feugier, P., Flinn, I. W., Gasiorowski, R., Greil, R., Illés, Á., Johnson, N. A., Larouche, J.-F., Lugtenburg, P. J., Patti, C., et al. (2021) · Blood · doi:10.1182/blood.2020006578 · Cited by 166
Sehn, L. H., Martelli, M., Trněný, M., Liu, W., Bolen, C. R., Knapp, A., Sahin, D. G., Sellam, G., & Vitolo, U. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00900-7 · Cited by 159
Li, A. M., Hucks, G., DiNofia, A. M., Seif, A. E., Teachey, D. T., Baniewicz, D., Callahan, C. A., Fasano, C., McBride, B., Gonzalez, V. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112572 · Cited by 156
Nowakowski, G. S., & Czuczman, M. S. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e449 · Cited by 150
Persky, D. O., Li, H., Stephens, D. M., Park, S. I., Bartlett, N. L., Swinnen, L. J., Barr, P. M., Winegarden, J. D., Constine, L. S., FitzGerald, T. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00999 · Cited by 140
Sermer, D. J., Batlevi, C. L., Palomba, M. L., Shah, G. L., Lin, R. J., Perales, M., Scordo, M., Dahi, P. B., Pennisi, M., Afuye, A. O., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002118 · Cited by 127
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
Ross, S. L., Sherman, M., McElroy, P. L., Lofgren, J. A., Moody, G. E., Baeuerle, P. A., Coxon, A., & Arvedson, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183390 · Cited by 118
Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103019 · Cited by 114
Schöder, H. M., Polley, M. C., Knopp, M. V., Hall, N. C., Kostakoglu, L., Zhang, J., Higley, H. R., Kelloff, G. J., Liu, H., Zelenetz, A. D., et al. (2020) · Blood · doi:10.1182/blood.2019003277 · Cited by 95
Chong, E. A., Svoboda, J., Nasta, S. D., Landsburg, D. J., Winchell, N., Napier, E. B., Mato, A. R., Melenhorst, J. J., Ruella, M., Lacey, S. F., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119502 · Cited by 84
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K., Chamuleau, M. E. D., Lewis, D. J., Sureda, A. M., Cunningham, D., Oliveri, R. S., et al. (2020) · Blood · doi:10.1182/blood-2020-133820 · Cited by 66
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Frigault, M. J., Armand, P. A., Redd, R. A., Jeter, E., Merryman, R. W., Coleman, K. C., Herrera, A. F., Dahi, P. B., Nieto, Y. L., LaCasce, A. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000784 · Cited by 64
Jacobson, C. A., Westin, J. R., Miklos, D. B., Herrera, A. F., Lee, J., Seng, J., Rossi, J. M., Sun, J., Dong, J., Roberts, Z. J., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-ct055 · Cited by 59
Hutchings, M., Carlo‐Stella, C., Bachy, E., Offner, F. C., Morschhauser, F., Crump, M., Iacoboni, G., Sureda, A. M., Martínez‐López, J., Lundberg, L., et al. (2020) · Blood · doi:10.1182/blood-2020-136044 · Cited by 56
Feldman, T. A., Mato, A. R., Chow, K. F., Protomastro, E., Yannotti, K., Bhattacharyya, P. K., Yang, X. Y., Donato, M. L., Rowley, S. D., Carini, C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12846 · Cited by 52
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Torka, P., Kothari, S. K., Sundaram, S., Li, S., Medeiros, L. J., Ayers, E. C., Landsburg, D. J., Bond, D. A., Maddocks, K. J., Giri, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000875 · Cited by 45
Self-citationPhillips, T. J., Olszewski, A. J., Munoz, J. L., Kim, T. M., Yoon, D. H., Greil, R., Westin, J. R., Jaeger, U., Canales, M. Á., Chen, C. S., et al. (2020) · Blood · doi:10.1182/blood-2020-136295 · Cited by 44
Neelapu, S. S., Dickinson, M. J., Ulrickson, M. L., Oluwole, O. O., Herrera, A. F., Thiéblemont, C., Ujjani, C. S., Lin, Y., Riedell, P. A., Kekre, N. K., et al. (2020) · Blood · doi:10.1182/blood-2020-134449 · Cited by 44
Ohmachi, K., Kinoshita, T., Tobinai, K., Ogawa, G., Mizutani, T., Yamauchi, N., Fukuhara, N., Uchida, T., Yamamoto, K., Miyazaki, K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002567 · Cited by 29
Seymour, E. K., Khan, H. Y., Li, Y., Chaker, M., Muqbil, I., Aboukameel, A., Ramchandren, R., Houde, C. A., Sterbis, G., Yang, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4929 · Cited by 26
Carreau, N. A., Armand, P. A., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., Ramchandren, R., Hamid, M. S., Assouline, S. E., Santiago, R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16756 · Cited by 24
Self-citationJaeger, U., Worel, N., McGuirk, J. P., Riedell, P. A., Fleury, I., Borchmann, P., Chu, J., Abdelhady, A. M., Forcina, A., Pacaud, L. B., et al. (2019) · Blood · doi:10.1182/blood-2019-129120 · Cited by 20
Zijlstra, J. M., Burggraaff, C. N., Kersten, M. J., & Barrington, S. F. (2016) · Haematologica · doi:10.3324/haematol.2016.142752 · Cited by 16
Karmali, R., Galvez, C., Hamadani, M., Gordon, L. I., Winter, J. N., Ma, S., Nelson, V. M., Fenske, T. S., Shah, N. N., Jagadeesh, D., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011369 · Cited by 8
Cited by
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion
Odstrcil, M. S., Lee, C. J., Sobieski, C., Weisdorf, D., & Couriel, D. (2024) · Blood Reviews · doi:10.1016/j.blre.2023.101136 · Cited by 50
Shen, H., Lian, Y., Yin, J., Zhu, M., Yang, C., Tu, C., Peng, Y., Li, X., & Zhang, J. (2023) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.122.014829 · Cited by 30
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2504719 · Cited by 5
Metadata
- Authors
- Susanibar‐Adaniya, S., & Barta, S. K.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2021-03-19
- Volume
- 96
- Issue
- 5
- Pages
- 617-629
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3133955595
- Cited by
- 388
- References
- 72
- FWCI
- 36.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.